Cure Parkinson's Approves Funding for New Iron Removing Drug
Cure Parkinson’s continues to champion iron chelation for Parkinson's. Trustees have now awarded a grant to develop the next generation of iron reducing drugs.
Learn more
The ADepT-PD Trial (nortriptyline)
This trial is recruiting 408 people in 30 centres across the UK. Funded by the NIHR with support from Cure Parkinson’s, the trial lead is Professor Anette Schrag, the Royal Free Hospital, London. Cure Parkinson’s is supporting a sub-study of this trial which will be…
The Bydureon (exenatide) Phase lll Trial
Cure Parkinson’s is delighted to be supporting two sub-studies within the Bydureon phase lll trial which has begun recruiting from six sites in the UK. This phase III efficacy trial in a larger cohort is the next stage in a programme of trials and research…
PD Frontline
As research has expanded in the area of Parkinson’s genetics, researchers have been able to uncover a number of genes which have been linked to an increased risk of developing Parkinson’s. About 10% of Parkinson’s diagnoses are linked to a genetic cause. Researchers believe that…